Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Malfunctioning Transport Protein Causes Plaque Buildup in Alzheimer's Disease

By LabMedica International staff writers
Posted on 21 Jul 2009
A malfunction in the network of cells that forms the blood brain barrier allows the toxic buildup of amyloid plaque that characterizes Alzheimer's disease.

Investigators at the Saint Louis University School of Medicine (MO, USA) worked with a mouse model of human Alzheimer's disease to study the action of low-density lipoprotein receptor related protein-1 (LRP-1), the major brain-to-blood transporter of amyloid-beta proteins at the blood-brain barrier (BBB). More...
For this purpose, they developed specific antisense RNA to block the synthesis of LRP-1 and thereby deplete it from the cells of the BBB.

Results of this study, published in the July 2009 issue of the Journal of Alzheimer's Disease, revealed that these antisense RNAs in comparison to random antisense RNA selectively decreased LRP-1 expression, reduced BBB clearance of amyloid-beta protein, increased brain levels of amyloid-beta protein, and impaired learning ability and recognition memory in mice.

Having confirmed the importance of LRP-1 in transporting amyloid-beta protein out of the brain, the investigators looked at the factors that could affect LRP-1's ability to function. They reported in the May 2009 issue of the journal Brain Behavior and Immunity that inflammation was directly linked to the malfunction of LRP-1. They induced inflammation in the brains of mice with lipopolysaccharide (LPS) and found that inflammation increased brain levels of amyloid-beta protein by three mechanisms: increased influx, decreased efflux, and increased neuronal production.

Treatment of the mice with the anti-inflammatory drug indomethacin prevented inhibition of LRP-1 and tended to lower the concentration of amyloid-beta protein in the brains of the animals.

"We induced inflammation in mice and found that it turned off the LRP pump that lets amyloid-beta protein exit the brain into the bloodstream. It also revved up an entrance pump that transports amyloid-beta into the brain. Both of these actions would increase the amount of amyloid-beta protein in the brain," said senior author of both papers Dr. William A. Banks, professor of geriatrics and pharmacological and physiological science at the Saint Louis University School of Medicine. "Nonsteroidal anti-inflammatory drugs, especially indomethacin, have been associated with protection against Alzheimer's disease. Our work could influence that debate and thinking at the patient-care level."

Related Links:
Saint Louis University School of Medicine




Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.